Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen-ultraviolet A and merocyanine 540-visible light methods.
Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralen-ultraviolet A and merocyanine 540-visible light methods.
复制标题
保留其体外特性的血小板悬浮液中的病毒灭活：补骨脂素-紫外线A和部花青540-可见光方法的比较。
DOI：
10.1046/j.1537-2995.1991.31691306242.x
复制
发表时间：
1991
期刊：
影响因子：
2.9
通讯作者：
Benade,LE
中科院分区：
文献类型：
--
作者：
Dodd,RY;Moroff,G;Wagner,S;Dabay,MH;Dorfman,E;George,V;Ribeiro,A;Shumaker,J;Benade,LE
比较了两种根本不同的光化学方法在血小板悬液中灭活模型病毒的能力。使用具有可见光的Mercury 540（MC 540）作为针对病毒膜的氧依赖性化学物质的实例，并且使用具有紫外线A光（UVA）的氨甲基三甲基补骨脂素（AMT）作为核酸定向系统的实例。确定了培养皿中的抗病毒条件，并研究了这些程序对塑料储存容器中血小板悬浮液的影响。浓度在10至150 μ mol范围内的光化学物质，用30至60分钟的可见光（MC 540）或1至2分钟的UVA（AMT）容易灭活5至6 log 10的水泡性口炎病毒（VSV）和血小板悬浮液中的其他模型病毒，只要通过使用合成血小板储存介质将血浆浓度降低至约15%。当血小板用MC 540和可见光处理时，细胞外pH、形态评分和聚集反应显著下降。然而，用136 mumol/L的AMT和1 - 3分钟的UVA治疗可以使血小板悬液中的VSV降低5 log 10，血小板特征保留4天，特别是如果治疗期间氧气水平降低。这些研究表明，AMT‐UVA处理符合血小板悬液中病毒灭活的初始要求。
The ability of two fundamentally different photochemical procedures to inactivate model viruses in platelet suspensions was compared. Merocyanine 540 (MC 540) with visible light was used as an example of an oxygen‐dependent chemical‐directed at the viral membrane, and aminomethyl trimethyl psoralen (AMT) with ultraviolet A light (UVA) was used as an example of a nucleic acid‐directed system. Antiviral conditions in petri dishes were identified and the effects of these procedures on platelet suspensions in plastic storage containers were studied. Concentrations of photochemicals in the 10 to 150 mumol range with 30 to 60 minutes of visible light (MC 540) or 1 to 2 minutes of UVA (AMT) readily inactivated 5 to 6 log10 of vesicular stomatitis virus (VSV) and other model viruses in platelet suspensions, provided the plasma concentration was reduced to about 15 percent by the use of a synthetic platelet storage medium. Extracellular pH, morphology scores, and aggregation response dropped markedly when platelets were treated with MC 540 and visible light. However, treatment with 136 mumol per L of AMT and 1 to 3 minutes of UVA could inactivate 5 log10 of VSV in platelet suspensions with retention of platelet characteristics for 4 days, particularly if oxygen levels were reduced during treatment. These studies demonstrate that AMT‐UVA treatment meets the initial requirements for virus inactivation in platelet suspensions.